Halozyme Therapeutics (HALO) Current Deferred Revenue (2010 - 2023)

Halozyme Therapeutics (HALO) has 14 years of Current Deferred Revenue data on file, last reported at $667000.0 in Q3 2023.

• On a quarterly basis, Current Deferred Revenue fell 81.4% year-over-year to $667000.0 in Q3 2023; TTM through Sep 2023 was $667000.0, a 81.4% decrease from a year earlier, with the FY2022 full-year figure at $3.2 million, down 24.09% from the prior year.
• Current Deferred Revenue for Q3 2023 stood at $667000.0, down from $3.1 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for HALO reached as high as $6.9 million in Q2 2022 and fell as low as $667000.0 in Q3 2023.
• Historically, Current Deferred Revenue has averaged $3.6 million across 5 years, with a median of $3.8 million in 2022.
• Across the five-year window, Current Deferred Revenue slumped 92.25% in 2019 and surged 604.95% in 2021, its largest moves.
• Year by year, Current Deferred Revenue stood at $4.0 million in 2019, then sank by 56.48% to $1.7 million in 2020, then jumped by 144.9% to $4.3 million in 2021, then retreated by 24.09% to $3.2 million in 2022, then slumped by 79.45% to $667000.0 in 2023.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $667000.0 in Q3 2023, $3.1 million in Q2 2023, and $5.5 million in Q1 2023.